Clinical Trial

Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study will analyze the clinical indicators, imaging data, and serum biomarkers of Alzheimer's disease (AD) patients receiving different doses of the medication before and after treatment. It aims to clarify whether the therapeutic efficacy in the low-dose group is equivalent to that in the recommended-dose group, and meanwhile to determine the optimal dose range for effective pharmacotherapy.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07505095
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Alzheimer Disease (AD), Alzheimer Dementia, MCI-AD, Early Stage Alzheimer's Disease
Enrollment 140 participants
Start Date 2026-04-30
Primary Completion 2027-04-30 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-01